- Home
- FISK vs DNLI Comparison
FISK vs DNLI Comparison
Compare FISK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISK
- DNLI
- Stock Information
- Founded
- FISK N/A
- DNLI 2013
- Country
- FISK
- DNLI United States
- Employees
- FISK 666
- DNLI N/A
- Industry
- FISK
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FISK
- DNLI Health Care
- Exchange
- FISK NYSE
- DNLI Nasdaq
- Market Cap
- FISK 2.4B
- DNLI 2.1B
- IPO Year
- FISK N/A
- DNLI 2017
- Fundamental
- Price
- FISK $7.76
- DNLI $14.78
- Analyst Decision
- FISK
- DNLI Strong Buy
- Analyst Count
- FISK 0
- DNLI 16
- Target Price
- FISK N/A
- DNLI $37.57
- AVG Volume (30 Days)
- FISK N/A
- DNLI 1.2M
- Earning Date
- FISK N/A
- DNLI 05-06-2025
- Dividend Yield
- FISK N/A
- DNLI N/A
- EPS Growth
- FISK N/A
- DNLI N/A
- EPS
- FISK N/A
- DNLI N/A
- Revenue
- FISK N/A
- DNLI N/A
- Revenue This Year
- FISK N/A
- DNLI N/A
- Revenue Next Year
- FISK N/A
- DNLI $497.02
- P/E Ratio
- FISK N/A
- DNLI N/A
- Revenue Growth
- FISK N/A
- DNLI N/A
- 52 Week Low
- FISK N/A
- DNLI $13.67
- 52 Week High
- FISK N/A
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- FISK 35.94
- DNLI 39.87
- Support Level
- FISK $7.58
- DNLI $13.67
- Resistance Level
- FISK $8.28
- DNLI $14.90
- Average True Range (ATR)
- FISK 0.02
- DNLI 0.76
- MACD
- FISK 0.01
- DNLI 0.15
- Stochastic Oscillator
- FISK 25.71
- DNLI 42.53
About FISK EMPIRE STATE REALTY OP LIM PARTNER
Empire State Realty OP LP is the operating partner of Empire State Realty Inc. The company along with its partner manages, operates, acquires and repositions properties in Manhattan and the greater New York metropolitan area. The firm operates in two segments, Real Estate and Observatory. Through the Real Estate segment, it offers services related to the ownership, management, operation, acquisition, repositioning and disposition of its real estate assets. Under the Observatory segment, it operates the two observatories of the Empire State Building. The company generates maximum revenue from the Real Estate segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.